FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366998853> ?p ?o ?g. }

• W4366998853 abstract "Abstract Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to castration-resistant prostate cancer (CRPC). Second generation hormonal therapies such as abiraterone acetate and enzalutamide are typically given to men with CRPC. However, these treatments are not curative and typically prolong survival only by a few months. Several resistance mechanisms contribute to this lack of efficacy such as the emergence of AR mutations, AR amplification, lineage plasticity, AR splice variants (AR-Vs) and increased kinase signaling. Having identified SRC kinase as a key tyrosine kinase enriched in CRPC patient tumors from our previous work, we evaluated whether inhibition of SRC kinase synergizes with enzalutamide or chemotherapy in several prostate cancer cell lines expressing variable AR isoforms. We observed robust synergy between the SRC kinase inhibitor, saracatinib, and enzalutamide, in the AR-FL+/AR-V+ CRPC cell lines, LNCaP95 and 22Rv1. We also observed that saracatinib significantly decreases AR Y 534 phosphorylation, a key SRC kinase substrate residue, on AR-FL and AR-Vs, along with the AR regulome, supporting key mechanisms of synergy with enzalutamide. Lastly, we also found that the saracatinib-enzalutamide combination reduced DNA replication compared to the saracatinib-docetaxel combination, resulting in marked increased apoptosis. By elucidating this combination strategy, we provide pre-clinical data that suggests combining SRC kinase inhibitors with enzalutamide in select patients that express both AR-FL and AR-Vs." @default.
• W4366998853 created "2023-04-27" @default.
• W4366998853 creator A5023804206 @default.
• W4366998853 creator A5025141753 @default.
• W4366998853 creator A5033796700 @default.
• W4366998853 creator A5034691008 @default.
• W4366998853 creator A5046292926 @default.
• W4366998853 creator A5049481020 @default.
• W4366998853 creator A5062157317 @default.
• W4366998853 creator A5065318155 @default.
• W4366998853 date "2023-04-25" @default.
• W4366998853 modified "2023-10-10" @default.
• W4366998853 title "Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer" @default.
• W4366998853 cites W1575345943 @default.
• W4366998853 cites W1772185780 @default.
• W4366998853 cites W1967789049 @default.
• W4366998853 cites W1975120553 @default.
• W4366998853 cites W1984373702 @default.
• W4366998853 cites W1996776596 @default.
• W4366998853 cites W2024648144 @default.
• W4366998853 cites W2046837085 @default.
• W4366998853 cites W2055013229 @default.
• W4366998853 cites W2057472767 @default.
• W4366998853 cites W2059286602 @default.
• W4366998853 cites W2074429860 @default.
• W4366998853 cites W2078400569 @default.
• W4366998853 cites W2080748037 @default.
• W4366998853 cites W2085847636 @default.
• W4366998853 cites W2087998073 @default.
• W4366998853 cites W2091926537 @default.
• W4366998853 cites W2096439168 @default.
• W4366998853 cites W2105762010 @default.
• W4366998853 cites W2111047881 @default.
• W4366998853 cites W2119504728 @default.
• W4366998853 cites W2128628205 @default.
• W4366998853 cites W2131296758 @default.
• W4366998853 cites W2142100128 @default.
• W4366998853 cites W2146391441 @default.
• W4366998853 cites W2148643283 @default.
• W4366998853 cites W2156215080 @default.
• W4366998853 cites W2165846310 @default.
• W4366998853 cites W2171020858 @default.
• W4366998853 cites W2179438025 @default.
• W4366998853 cites W2195725578 @default.
• W4366998853 cites W2402183197 @default.
• W4366998853 cites W2419426348 @default.
• W4366998853 cites W2494960642 @default.
• W4366998853 cites W2806440020 @default.
• W4366998853 cites W2892078335 @default.
• W4366998853 cites W2949193973 @default.
• W4366998853 cites W2966606200 @default.
• W4366998853 cites W3209637856 @default.
• W4366998853 cites W4226211056 @default.
• W4366998853 cites W4242289937 @default.
• W4366998853 doi "https://doi.org/10.1101/2023.04.22.537922" @default.
• W4366998853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37163118" @default.
• W4366998853 hasPublicationYear "2023" @default.
• W4366998853 type Work @default.
• W4366998853 citedByCount "0" @default.
• W4366998853 crossrefType "posted-content" @default.
• W4366998853 hasAuthorship W4366998853A5023804206 @default.
• W4366998853 hasAuthorship W4366998853A5025141753 @default.
• W4366998853 hasAuthorship W4366998853A5033796700 @default.
• W4366998853 hasAuthorship W4366998853A5034691008 @default.
• W4366998853 hasAuthorship W4366998853A5046292926 @default.
• W4366998853 hasAuthorship W4366998853A5049481020 @default.
• W4366998853 hasAuthorship W4366998853A5062157317 @default.
• W4366998853 hasAuthorship W4366998853A5065318155 @default.
• W4366998853 hasBestOaLocation W43669988531 @default.
• W4366998853 hasConcept C108636557 @default.
• W4366998853 hasConcept C121608353 @default.
• W4366998853 hasConcept C126322002 @default.
• W4366998853 hasConcept C134018914 @default.
• W4366998853 hasConcept C143998085 @default.
• W4366998853 hasConcept C170493617 @default.
• W4366998853 hasConcept C184235292 @default.
• W4366998853 hasConcept C2776551883 @default.
• W4366998853 hasConcept C2777899217 @default.
• W4366998853 hasConcept C2777911890 @default.
• W4366998853 hasConcept C2780192828 @default.
• W4366998853 hasConcept C2781190966 @default.
• W4366998853 hasConcept C502942594 @default.
• W4366998853 hasConcept C61367390 @default.
• W4366998853 hasConcept C71315377 @default.
• W4366998853 hasConcept C71924100 @default.
• W4366998853 hasConcept C86803240 @default.
• W4366998853 hasConcept C95444343 @default.
• W4366998853 hasConceptScore W4366998853C108636557 @default.
• W4366998853 hasConceptScore W4366998853C121608353 @default.
• W4366998853 hasConceptScore W4366998853C126322002 @default.
• W4366998853 hasConceptScore W4366998853C134018914 @default.
• W4366998853 hasConceptScore W4366998853C143998085 @default.
• W4366998853 hasConceptScore W4366998853C170493617 @default.
• W4366998853 hasConceptScore W4366998853C184235292 @default.
• W4366998853 hasConceptScore W4366998853C2776551883 @default.
• W4366998853 hasConceptScore W4366998853C2777899217 @default.
• W4366998853 hasConceptScore W4366998853C2777911890 @default.
• W4366998853 hasConceptScore W4366998853C2780192828 @default.
• W4366998853 hasConceptScore W4366998853C2781190966 @default.
• W4366998853 hasConceptScore W4366998853C502942594 @default.

• next